Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg ups BP to 'buy' after 'significantly stronger' results

(Sharecast News) - Berenberg upgraded BP on Thursday to 'buy' from 'hold' and hiked the price target to 500p from 385p following "significantly stronger" results through Q2 2025 combined with the recent positive exploration news flow. The bank said the key driver of the improved outlook is a stronger free cash flow outlook, helped by lower capex, progress on the cost-cutting programme and recovery in the downstream business.

"At the same time, exploration success, particularly the potential at the Bumerangue field in Brazil, may offer investors comfort on the medium- to longer-term outlook for the upstream business," Berenberg said.

It noted that BP's new chairman is kicking off his appointment with further reviews on both costs and the broader portfolio, pointing to an ongoing focus on shareholder returns.

"The $20bn divestment plan should enable both lower net debt and the continuation of attractive buybacks in 2026, leaving a 10% total cash shareholder return (a 6.2% dividend yield)," it said.

Berenberg increased its earnings per share estimates 11%/8% for 2025/26 respectively, driven by higher gas and refining assumptions.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.